ProMIS Neurosciences second quarter 2026 loss of $1.28 beats estimates with zero ARIA-E cases

ProMIS Neurosciences reported a second quarter 2026 net loss that narrowed on a per-share basis compared to the previous year, outperforming analyst expectations. The company significantly strengthened its financial position following a $70.1 million private placement in January, extending its operational runway through the completion of its lead clinical trial.

Key Highlights

• Reported a net loss of $11.7 million, or $1.28 per share, beating the estimated loss of $1.38 per share.
• Achieved a favorable safety profile for PMN310 with zero cases of ARIA-E (brain swelling) across 136 evaluable participants in the PRECISE-AD trial.
• Cash and short-term investments rose to $53.4 million, compared to $6.1 million at year-end 2025, funding operations through 2027.
• Blinded interim biomarker analysis showed declines of approximately 15% in plasma pTau217 and 13.3% in CSF MTBR-tau243 through 169 days of treatment.